Topic: non-small cell lung cancer
More results are out from a trial of Roche’s Tecentriq in lung cancer, but industry watchers still don’t have many of the answers they’re looking for.
Bristol-Myers Squibb Friday touted strong Opdivo results for lung cancer in previously treated Chinese patients.
AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new editorial should do just that, one analyst says.
Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.
Lilly's new cancer drug Verzenio faces two tough rivals—Pfizer's Ibrance and Novartis' Kisquali—but the company says it's standing out from the crowd.
With Opdivo's third straight sales beat of the year in the books, the company has laid investors' 2017 growth worries to rest.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Keytruda has built up an imposing lead in the I-O lung cancer space, and Merck is touting more positive survival data to keep that lead intact.
Eli Lilly’s Verzenio needs to stand out in a crowd, and now it's less likely that a lung cancer approval could be the solution.
Eli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too.